Latest / Breaking News To Trading Moves
Relacorilant Rejection: Market Impacts on Biotech and Therapeutics
FDA Rejects Corcept’s Relacorilant for Cushing Syndrome-Related Hypertension
What happened
The US FDA declined to approve Corcept Therapeutics’ relacorilant for hypertension in patients with hypercortisolism (Cushing syndrome), citing insufficient evidence of effectiveness and an unclear benefit-risk profile. Corcept said it plans to meet with the FDA on next steps, and shares fell sharply on the news.
Why it matters for markets
A “complete response” like this can reset timelines by years, force new trials, and pressure funding for small/mid-cap biotechs. At the same time, it can shift share…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.